Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): real-world data on survival and safety from the German expanded-access program (EAP)
checkpoint inhibitor, NSCLC, PD-L1, real world, survival
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
21 October 2020
|
| In: |
Lung cancer
Year: 2020, Jahrgang: 150, Heft: 12, Pages: 114-122 |
| ISSN: | 1872-8332 |
| DOI: | 10.1016/j.lungcan.2020.10.006 |
| Online-Zugang: | Resolving-System, lizenzpflichtig: https://doi.org/10.1016/j.lungcan.2020.10.006
|
| Verfasserangaben: | Martin Faehling, Christian Schumann, Petros Christopoulos, Petra Hoffknecht, Jürgen Alt, Marlitt Horn, Stephan Eisenmann, Anke Schlenska-Lange, Philipp Schütt, Felix Steger, Wolfgang M. Brückl, Daniel C. Christoph |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1753286026 | ||
| 003 | DE-627 | ||
| 005 | 20220819155628.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210407s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.lungcan.2020.10.006 |2 doi | |
| 035 | |a (DE-627)1753286026 | ||
| 035 | |a (DE-599)KXP1753286026 | ||
| 035 | |a (OCoLC)1341403706 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Faehling, Martin |d 1966- |e VerfasserIn |0 (DE-588)1171164823 |0 (DE-627)1040402135 |0 (DE-576)513619356 |4 aut | |
| 245 | 1 | 0 | |a Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC) |b real-world data on survival and safety from the German expanded-access program (EAP) |c Martin Faehling, Christian Schumann, Petros Christopoulos, Petra Hoffknecht, Jürgen Alt, Marlitt Horn, Stephan Eisenmann, Anke Schlenska-Lange, Philipp Schütt, Felix Steger, Wolfgang M. Brückl, Daniel C. Christoph |
| 264 | 1 | |c 21 October 2020 | |
| 300 | |b Diagramme | ||
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 04.02.2022 | ||
| 520 | |a checkpoint inhibitor, NSCLC, PD-L1, real world, survival | ||
| 700 | 1 | |a Schumann, Christian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Christopoulos, Petros |d 1977- |e VerfasserIn |0 (DE-588)138659702 |0 (DE-627)604886756 |0 (DE-576)308488067 |4 aut | |
| 700 | 1 | |a Hoffknecht, Petra |e VerfasserIn |4 aut | |
| 700 | 1 | |a Alt, Jürgen |e VerfasserIn |4 aut | |
| 700 | 1 | |a Horn, Marlitt |e VerfasserIn |4 aut | |
| 700 | 1 | |a Eisenmann, Stephan |d 1977- |e VerfasserIn |0 (DE-588)13283474X |0 (DE-627)690917163 |0 (DE-576)299447103 |4 aut | |
| 700 | 1 | |a Schlenska-Lange, Anke |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schütt, Philipp |e VerfasserIn |4 aut | |
| 700 | 1 | |a Steger, Felix |e VerfasserIn |4 aut | |
| 700 | 1 | |a Brückl, Wolfgang M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Christoph, Daniel C. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Lung cancer |d Amsterdam [u.a.] : Elsevier, 1985 |g 150(2020), 12, Seite 114-122 |h Online-Ressource |w (DE-627)320649733 |w (DE-600)2025812-4 |w (DE-576)264627539 |x 1872-8332 |7 nnas |a Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC) real-world data on survival and safety from the German expanded-access program (EAP) |
| 773 | 1 | 8 | |g volume:150 |g year:2020 |g number:12 |g pages:114-122 |g extent:9 |a Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC) real-world data on survival and safety from the German expanded-access program (EAP) |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.lungcan.2020.10.006 |x Resolving-System |z lizenzpflichtig |
| 951 | |a AR | ||
| 992 | |a 20220204 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 138659702 |a Christopoulos, Petros |m 138659702:Christopoulos, Petros |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PC138659702 |e 950000PC138659702 |e 950900PC138659702 |e 50000PC138659702 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 3 | ||
| 999 | |a KXP-PPN1753286026 |e 4051293319 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedKey":"2020","dateIssuedDisp":"21 October 2020"}],"language":["eng"],"id":{"doi":["10.1016/j.lungcan.2020.10.006"],"eki":["1753286026"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"physDesc":[{"noteIll":"Diagramme","extent":"9 S."}],"person":[{"family":"Faehling","display":"Faehling, Martin","given":"Martin","role":"aut"},{"role":"aut","given":"Christian","family":"Schumann","display":"Schumann, Christian"},{"given":"Petros","family":"Christopoulos","display":"Christopoulos, Petros","role":"aut"},{"given":"Petra","family":"Hoffknecht","display":"Hoffknecht, Petra","role":"aut"},{"role":"aut","family":"Alt","display":"Alt, Jürgen","given":"Jürgen"},{"role":"aut","given":"Marlitt","family":"Horn","display":"Horn, Marlitt"},{"role":"aut","display":"Eisenmann, Stephan","family":"Eisenmann","given":"Stephan"},{"given":"Anke","display":"Schlenska-Lange, Anke","family":"Schlenska-Lange","role":"aut"},{"role":"aut","display":"Schütt, Philipp","family":"Schütt","given":"Philipp"},{"given":"Felix","display":"Steger, Felix","family":"Steger","role":"aut"},{"display":"Brückl, Wolfgang M.","family":"Brückl","given":"Wolfgang M.","role":"aut"},{"given":"Daniel C.","display":"Christoph, Daniel C.","family":"Christoph","role":"aut"}],"title":[{"title":"Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC)","subtitle":"real-world data on survival and safety from the German expanded-access program (EAP)","title_sort":"Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC)"}],"relHost":[{"language":["eng"],"id":{"eki":["320649733"],"zdb":["2025812-4"],"issn":["1872-8332"]},"type":{"media":"Online-Ressource","bibl":"periodical"},"origin":[{"publisherPlace":"Amsterdam [u.a.]","dateIssuedDisp":"1985-","publisher":"Elsevier","dateIssuedKey":"1985"}],"part":{"volume":"150","pages":"114-122","text":"150(2020), 12, Seite 114-122","year":"2020","extent":"9","issue":"12"},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Lung cancer","title":"Lung cancer","subtitle":"journal of the International Association for the Study of Lung Cancer"}],"disp":"Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC) real-world data on survival and safety from the German expanded-access program (EAP)Lung cancer","recId":"320649733","pubHistory":["1.1985 -"],"note":["Gesehen am 20.02.20"]}],"name":{"displayForm":["Martin Faehling, Christian Schumann, Petros Christopoulos, Petra Hoffknecht, Jürgen Alt, Marlitt Horn, Stephan Eisenmann, Anke Schlenska-Lange, Philipp Schütt, Felix Steger, Wolfgang M. Brückl, Daniel C. Christoph"]},"recId":"1753286026","note":["Gesehen am 04.02.2022"]} | ||
| SRT | |a FAEHLINGMADURVALUMAB2120 | ||